AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune dosed the first patients in Cohort AD4 of the Phase 1b/2 ABATE trial, triggering a $12 million milestone payment from partner Takeda. The trial evaluates ACI-24 for Alzheimer's prevention, with 12-month data from earlier cohorts expected in Q2 2026.
Key figures
- Drug Name
- ACI-24
- Phase Of Trial
- Phase 1b/2
- Cohort ad4 initial patients
- 36
- Prior cohorts total patients
- 74
- Cohort ad4 potential total patients
- 112
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.